Approach

Identify emerging companies with innovative solutions to major medical problems that are likely to confer a sustainable competitive advantage over current standard of care.

Evaluate companies across multiple dimensions including scientific and clinical data, technological advantage, quality of management, and balance sheet. 

Seek to diversify exposure across technology platforms, target diseases, and modalities (e.g. therapeutic, device, diagnostic). 

Areas of scientific interest include gene editing, engineered cell therapies, DNA sequencing, regenerative medicine, synthetic biology, and nanomedicine. 

Identify emerging companies with innovative solutions to major medical problems that are likely to confer a sustainable competitive advantage over current standard of care.

Evaluate companies across multiple dimensions including scientific and clinical data, technological advantage, quality of management, and balance sheet. 

Seek to diversify exposure across technology platforms, target diseases, and modalities (e.g. therapeutic, device, diagnostic). 

Areas of scientific interest include gene editing, engineered cell therapies, DNA sequencing, regenerative medicine, synthetic biology, and nanomedicine.